Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyHighmark BlueShield NENY NDC reporting policy upda…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedHighmark Blueshield NenyPolicy N/A

    Highmark List of Procedure Codes Requiring NDC

    Customize your policy alerts

    Sign up for all Highmark Blueshield Neny policy alerts

    Know when Highmark Blueshield Neny releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    A payer list of HCPCS/J-codes and other procedure codes for which submission of National Drug Code (NDC) information will be required beginning 1/01/2026; affects providers billing these codes to Highmark BlueShield of NENY.

    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyHighmark List of Procedure Codes Requiring NDC
    Policy CodePolicy N/A
    Change TypeAdded code list requiring NDC reporting
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionProviders must include the National Drug Code (NDC) on claims for the listed HCPCS/J- and related procedure codes beginning 01/01/2026.
    SourceLink
    POLICY UPDATE CHANGES

    Multiple J-codes (HCPCS) are designated as requiring NDC effective 1/01/2026.

    A comprehensive list of J‑ and related HCPC procedure codes that will require NDC reporting was provided effective 1/01/2026.

    01/01/2026date requirement begins
    NDC requiredpolicy action
    ~200+procedure codes listed (approx)
    partialdocument excerpt size

    Procedure codes that require NDC submission

    NDC submission requirement (code list)

    This file is a code list indicating which procedure codes will require an associated NDC when billed.

    An associated National Drug Code (NDC) is required on claims when billing any procedure code listed in this document (HCPCS/J/Q/S/Q99xx series entries).

    NDC submission criteria (billing requirement)

    Providers must include the NDC when billing the following HCPCS J‑codes (partial excerpt).

    ALL of the following

    • Example J-codes (partial)

      • J1000 – INJECTION, DEPO-ESTRADIOL CYPIONATE, UP TO 5 MG
      • J1010 – INJECTION, METHYLPREDNISOLONE ACETATE, 1 MG
    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyHighmark List of Procedure Codes Requiring NDC
    Policy CodePolicy N/A
    Change TypeAdded code list requiring NDC reporting
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionProviders must include the National Drug Code (NDC) on claims for the listed HCPCS/J- and related procedure codes beginning 01/01/2026.
    SourceLink
    On This Page
    Procedure codes that require NDC submissionExample and representative HCPCS / J / Q / S codesWhat providers must doDefinitions and key terms
  1. J1020 – INJECTION, METHYLPREDNISOLONE ACETATE, 20 MG
  2. Requirement effective 01/01/2026: include the corresponding NDC on claims for any listed J-code.

    NDC submission criteria for listed codes

    When submitting claims for any procedure codes enumerated below, providers must include the corresponding NDC on the claim.

    ALL of the following

    • Sample included J-codes

      • J2428 – Injection, paliperidone palmitate extended release, 1 mg
      • J2505 – Injection, pegfilgrastim, 6 mg
      • J2543 – Injection, piperacillin sodium/tazobactam, 1.125 grams
      • J3032 – Injection, eptinezumab-jjmr, 1 mg
      • J3055 – Injection, talquetamab-tgvs, 0.25 mg
    Operational rule: include the corresponding NDC when submitting claims for any of the enumerated procedure codes (effective 01/01/2026).

    NDC submission requirement

    Billing requirement: when billing for these procedure codes, providers must include the NDC for the drug product.

    ALL of the following

    • Representative codes requiring NDC

      • J7516 – Injection, cyclosporine, 250 mg
      • J7311 – Injection, fluocinolone acetonide, intravitreal implant (Retisert), 0.01 mg
      • Q0235 – Injection, monoclonal antibody products for COVID-19 (examples include post-exposure prophylaxis or treatment)
      • Q0237 – Injection, tocilizumab, for hospitalized adult patients with COVID-19
    Include NDC for the drug product when billing any listed HCPCS/J/Q code to Highmark BlueShield NENY (effective 01/01/2026).

    NDC submission requirement — code list

    Codes listed in this document require submission of associated NDCs when billed to Highmark BlueShield NENY.

    ALL of the following

    • Selected Q-/biosimilar/S-code examples

      • Q0239 – Injection, bamlanivimab-xxxx, 700 mg
      • Q0240 – Injection, casirivimab and imdevimab, 600 mg
      • Q5103 – Injection, Inflectra (biosimilar)
      • Q5109 – Injection, Infliximab-qbtx (biosimilar)
      • Q9991 – Injection, buprenorphine extended-release (Sublocade)
      • S0013 – Esketamine, nasal spray
    Effective date: requirement to submit NDC for listed codes begins 01/01/2026.

    Example and representative HCPCS / J / Q / S codes

    Example J/HCPCS codes requiring NDCmixed
    90378RESPIRATORY SYNCYTIAL VIRUS, MONOCLONAL ANTIBODY, RECOMBINANT, FOR INTRAMUSCULAR USE, 50 MG, EACH.
    C9399UNCLASSIFIED DRUGS OR BIOLOGICALS
    J0121INJECTION, OMADACYCLINE, 1 MG
    J0122INJECTION, ERAVACYCLINE, 1 MG
    J0135INJECTION, ADALIMUMAB, 20 MG
    J0218INJECTION, OLIPUDASE ALFA-RPCP, 1 MG
    J0248INJECTION, REMDESIVIR, 1 MG
    J0570Buprenorphine implant, 74.2 mg
    J0738Injection, lenacapavir, 1 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis
    Example J-codes from list (partial)HCPCS
    J1000INJECTION, DEPO-ESTRADIOL CYPIONATE, UP TO 5 MG
    J1010INJECTION, METHYLPREDNISOLONE ACETATE, 1 MG
    J1020INJECTION, METHYLPREDNISOLONE ACETATE, 20 MG
    Additional J-codes (partial)HCPCS
    J2505INJECTION, PEGFILGRASTIM, 6 MG
    J2543INJECTION, PIPERACILLIN SODIUM/TAZOBACTAM SODIUM, 1 GRAM/0.125 GRAMS (1.125 GRAMS)
    Sample J‑codes from list (document contains many more)HCPCS
    J2428Injection, paliperidone palmitate extended release (erzofri), 1 mg
    J2430INJECTION, PAMIDRONATE DISODIUM, PER 30 MG
    J2440INJECTION, PAPAVERINE HCL, UP TO 60 MG
    Examples of implant/infusion codesHCPCS
    J7311INJECTION, FLUOCINOLONE ACETONIDE, INTRAVITREAL IMPLANT (RETISERT), 0.01 MG
    J7312INJECTION, DEXAMETHASONE, INTRAVITREAL IMPLANT, 0.1 MG
    J7351Injection, bimatoprost, intracameral implant, 1 microgram
    Representative HCPCS/J/Q codes requiring NDCHCPCS
    J7516INJECTION, CYCLOSPORINE, 250 MG
    J7520SIROLIMUS, ORAL, 1 MG
    J9035INJECTION, CETUXIMAB, 10 MG
    J9310RITUXIMAB, 100 MG
    Q0138FERUMOXYTOL, 1 MG (non‑ESRD use)
    Q0220TIXAGEVIMAB AND CILGAVIMAB, 300 MG (pre‑exposure prophylaxis)
    J9999NOT OTHERWISE CLASSIFIED, ANTINEOPLASTIC DRUG
    Selected COVID-19 monoclonal antibody and related Q-codesHCPCSCovered
    Q0235Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg.
    Q0237Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
    Q0239INJECTION, BAMLANIVIMAB-XXXX, 700 MG
    Q0240INJECTION, CASIRIVIMAB AND IMDEVIMAB, 600 MG
    Representative biosimilar injectionsHCPCSCovered
    Q5100Injection, ustekinumab-kfce (yesintek), biosimilar
    Q5101Injection, filgrastim-sndz (Zarxio), biosimilar
    Q5112Injection, trastuzumab-dttb (Ontruzant), biosimilar
    Q5124Injection, ranibizumab-nuna (Byooviz), biosimilar
    Other included Q-/S- codesHCPCSCovered
    Q9991Injection, buprenorphine extended-release (Sublocade), LESS THAN OR EQUAL TO 100 MG
    S0013ESKETAMINE, NASAL SPRAY
    S5550INSULIN, RAPID ONSET; 5 UNITS
    S5553INSULIN, LONG ACTING; 5 UNITS
    Coding — Effective date and key metadata
    Policy effective date1/01/2026
    Action requiredProviders must include the National Drug Code (NDC) on claims for the listed procedure/HCPCS/J/Q codes beginning 1/01/2026.
    Codes explicitly present in sourceJ0218; J0248; J0738
    Examples of Q‑codes requiring NDCQ0235 (monoclonal antibody for COVID-19), Q0237 (tocilizumab for hospitalized COVID-19 patients)
    ScopeApplies to HCPCS/J‑codes, Q‑codes, biosimilars, S‑series and other drug procedure codes listed in the document when billed to Highmark BlueShield NENY.

    What providers must do

    Billing Rule

    NDC required on claims for listed procedure codes effective 01/01/2026

    Effective 01/01/2026, providers billing any of the procedure codes enumerated in this document must include the associated National Drug Code (NDC) on the claim.

    Billing Rule

    Include NDC for listed J-codes starting 01/01/2026

    Providers must include the NDC when submitting claims for the listed J‑/HCPCS procedure codes beginning 01/01/2026.

    Billing Rule

    Scope: injectables, infusions, implants and other drug administration codes

    The operational scope requires reporting the NDC on claims for injectable, infusion, implant, and other drug administration procedure codes included in the list when billed to the payer.

    Billing Rule

    Submit NDC when billing listed HCPCS/J- and Q-codes

    When billing any of the HCPCS/J- and Q-codes listed in this document, providers must submit the applicable NDC for the drug product on the claim.

    • Applies to HCPCS J-codes (e.g., J2505, J2543, J7311) and temporary Q-codes (see code list).
    • Submit the NDC associated with the specific drug product administered for each billed procedure code.
    Billing Rule

    Examples: Q0235, Q0237 require NDC

    Examples of listed Q-codes that require NDC reporting include Q0235 and Q0237 (monoclonal antibody products and tocilizumab) as shown in the code list.

    • Q0235 — Injection, monoclonal antibody products with an indication for post‑exposure prophylaxis or treatment of COVID‑19.
    • Q0237 — Injection, tocilizumab, for hospitalized adult patients with COVID‑19.
    Billing Rule

    Biosimilar HCPCS/Q-codes require NDC

    An extensive set of biosimilar Q‑series codes (Q5103–Q5130 and beyond) are included in the list and require submission of the NDC when billed.

    • Representative biosimilars in the list include Q5103 (Inflectra), Q5104 (Renflexis), Q5112 (trastuzumab biosimilar), Q5124 (ranibizumab biosimilar).
    • Submit the NDC for the specific biosimilar product administered.
    Billing Rule

    Other included drug codes (Q99xx, S-series, S555x) require NDC

    Additional drug-related codes such as Q99xx entries, S‑series procedure codes, and S555x insulin codes are included and require associated NDC submission.

    • Examples include Q9991–Q9999 entries, S0013 (esketamine nasal spray), and insulin codes S5550–S5553.
    • When billing these codes, include the NDC for the administered product.

    Definitions and key terms

    Procedure codes requiring NDC
    Requirement summaryProcedure codes listed (HCPCS/J- and related codes) require an associated NDC when billed to Highmark BlueShield NENY
    ScopeIncludes injectable, infusion, implant, Q- and S-series drug/biologic procedure codes enumerated in the list
    Provider obligationInclude the corresponding NDC on the claim for each listed procedure code
    NDC requirement — summary
    MandateNational Drug Code (NDC) must be submitted on claims for specified procedure codes
    Effective dateEffective 01/01/2026
    PayerHighmark BlueShield NENY
    NDC requirement for listed procedure codes
    DefinitionWhen submitting claims for any of the procedure codes enumerated in this list, providers must include the corresponding NDC on the claim
    Codes affectedJ‑codes and other HCPCS procedure codes listed in the document
    Operational startRequirement applies to claims submitted beginning 1/01/2026
    HCPC listing format
    List formatHCPC, 1 = Description (each line shows code then description)
    Columns shownCode (HCPCS/J/Q/S) and Description; unit or dosage information included where applicable
    Examples in listEntries such as J7516, J7520, and Q0138 follow the format 'code, Description = ...'
    Q-code entries
    What Q-codes representTemporary HCPCS codes for drugs/biologics; list includes monoclonal antibodies and COVID-19 therapeutics
    Indications notedSome Q-code entries include specific indications (e.g., pre-exposure prophylaxis, hospitalized COVID-19 patients)
    ExamplesQ0235 (monoclonal antibody products for COVID-19), Q0237 (tocilizumab for hospitalized COVID-19 patients)
    NDC reporting requirement
    Submission ruleNDC must be submitted when billing the specified HCPCS or Q codes listed in this document
    Included code typesJ-codes, Q-codes, and other HCPCS/S-series codes enumerated in the list
    ReasonTo identify the exact drug product administered for the billed procedure code
    Q-codes — explanatory notes
    Purpose of Q-codesTemporary HCPCS codes used to identify drugs, biologics, and other medical items (many are monoclonal antibodies or biosimilars)
    Biosimilar inclusionList contains numerous biosimilar Q-code entries (e.g., Q5100–Q5130 series)
    ExamplesQ5100–Q5112 (biosimilar injections) and other Q-codes for therapeutic biologics